Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00236054 | A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder | PHASE3 | COMPLETED | 440 | — | — | Oct 1, 2004 | Dec 1, 2005 | May 9, 2014 | 19 | United States |
| NCT00236067 | A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder | PHASE3 | COMPLETED | 440 | — | — | Oct 1, 2004 | Mar 1, 2006 | May 9, 2014 | 21 | United States |
| Name | Type | Description |
|---|---|---|
| Gabitril | DRUG | - |
Inclusion Criteria: * Subjects 18 to 64 years of age (inclusive) will be eligible to participate if they satisfy the DSM-IV-TR criteria for GAD, as well as meeting the required screening and baseline visit scores for a series of psychiatric evaluations (i.e., HAM-A, HADS, MADRS and CGI-S). Exclusi...